Evidence map›Paper›PMID 30656983›Full record

ArticleLeukemia & lymphoma2019

R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma.

Marcus Messmer, Hua-Ling Tsai, Ravi Varadhan, Lode J Swinnen, Richard J Jones, Richard F Ambinder, Satish P Shanbhag, Michael J Borowitz, Nina Wagner-Johnston

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Observational
  5. Prognostic significance of clinical characteristics andThe Journal of international medical research · 2022
    Article
  6. Mediastinal tumours and pseudo-tumours: a comprehensive review with emphasis on multidisciplinary approach.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Marcus Messmera Department of Oncology , Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Hua-Ling Tsaib Division of Biostatistics , Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Ravi Varadhanb Division of Biostatistics , Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Lode J Swinnena Department of Oncology , Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Richard J Jonesa Department of Oncology , Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Richard F Ambindera Department of Oncology , Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Satish P Shanbhaga Department of Oncology , Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Michael J Borowitzc Department of Pathology , Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Nina Wagner-Johnstona Department of Oncology , Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Johns Hopkins University · USSidney Kimmel Comprehensive Cancer Center · USJohns Hopkins Medicine · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
NCI NIH HHS P30 CA006973
6 · The paper itself

Abstract

Prior to the introduction of rituximab, primary mediastinal B-cell lymphoma (PMBCL) had high rates of treatment failure with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), prompting the use of consolidative mediastinal radiation or more intensive chemotherapy regimens. Cure rates improved dramatically with rituximab, but mediastinal radiation was still commonly employed with R-CHOP. We performed a retrospective review of patients treated with R-CHOP alone without radiation for PMBCL. Of 43 patients with PMBCL, 16 received R-CHOP alone. High-risk factors included 56% with bulky disease, 75% with elevated LDH, 25% with SVC syndrome, and 13% with stage IV disease. Three-year progression-free survival (PFS) and overall survival (OS) were 93% and 100% respectively. These results suggest that R-CHOP alone has a high cure rate in PMBCL while avoiding the side effects of mediastinal radiation.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAdolescentAdultCombined Modality TherapyCyclophosphamideDisease ManagementDoxorubicinFemaleHumansLymphoma, B-CellMaleMediastinal NeoplasmsMiddle AgedNeoplasm StagingPrednisonePrognosisCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristinediffuse large B-cell lymphomaDLBCLnon-Hodgkin lymphomaPMBCLPrimary mediastinal B-cell lymphomaR-CHOP

Identifiers

PMID30656983
PMCPMC6472975
OpenAlexW2910591463

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.